Baseline comorbidities in a population-based cohort of rheumatoid arthritis receiving biological therapy: Data from the Australian Rheumatology Association database
dc.contributor.author | Briggs, Andrew | |
dc.contributor.author | March, L. | |
dc.contributor.author | Lassere, M. | |
dc.contributor.author | Reid, C. | |
dc.contributor.author | Henderson, L. | |
dc.contributor.author | Murphy, B. | |
dc.contributor.author | van den Haak, R. | |
dc.contributor.author | Rischin, A. | |
dc.contributor.author | Staples, M. | |
dc.contributor.author | Buchbinder, R. | |
dc.date.accessioned | 2017-01-30T14:37:56Z | |
dc.date.available | 2017-01-30T14:37:56Z | |
dc.date.created | 2015-03-03T20:14:29Z | |
dc.date.issued | 2009 | |
dc.identifier.citation | Briggs, A. and March, L. and Lassere, M. and Reid, C. and Henderson, L. and Murphy, B. and van den Haak, R. et al. 2009. Baseline comorbidities in a population-based cohort of rheumatoid arthritis receiving biological therapy: Data from the Australian Rheumatology Association database. International Journal of Rheumatology. 2009: Article ID 861481. | |
dc.identifier.uri | http://hdl.handle.net/20.500.11937/39887 | |
dc.identifier.doi | 10.1155/2009/861481 | |
dc.description.abstract |
Aims. To describe the baseline characteristics of an Australian population-based cohort of rheumatoid arthritis (RA) patients commencing biological therapy. Methods. Descriptive analysis from the Australian Rheumatology Association Database (ARAD). Results. Up to October 2006, there were 681 RA patients taking biologics enrolled in ARAD. Baseline data were available for 624 (72% female, mean (SD) age 57.0 (12.5) years). Of these, 59.5% reported at least one comorbid condition, most commonly hypertension (35.7%) and osteoporosis (30.4%); 61 (9.8%) had a history of malignancy (35 nonmelanoma skin, 5 breast, 4 bowel, 5 cervix, 3 melanoma, 3 prostate and 1 each of lip, lung, myeloma, testis, uterus, vagina). Self-reported infections within the previous 6 months were common (71.5%). Conclusions. History of comorbidities, including recent infections, is common among Australian RA patients commencing biologics, and 10% have a history of malignancy. This may impact future evaluations of health outcomes among this population, including attribution of adverse events of biologic therapy. | |
dc.publisher | Hindawi Publishing Company | |
dc.title | Baseline comorbidities in a population-based cohort of rheumatoid arthritis receiving biological therapy: Data from the Australian Rheumatology Association database | |
dc.type | Journal Article | |
dcterms.source.volume | 2009 | |
dcterms.source.startPage | 1 | |
dcterms.source.endPage | 8 | |
dcterms.source.issn | 1687-9260 | |
dcterms.source.title | International Journal of Rheumatology | |
curtin.note |
This article is published under the Open Access publishing model and distributed under the terms of the Creative Commons License | |
curtin.department | School of Physiotherapy and Exercise Science | |
curtin.accessStatus | Open access |